Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Fineline Cube Apr 1, 2026
Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Fineline Cube Apr 1, 2026
Company Drug

BeOne’s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL/SLL and MCL

Fineline Cube Jan 8, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that its self‑developed Class 1 innovative drug...

Company Drug

XtalPi’s RTX-117 Wins NMPA IND for CMT Therapy

Fineline Cube Jan 8, 2026

ReviR Therapeutics, an incubated company of XtalPi (HKG: 2228), announced that RTX-117 has received Investigational...

Company Drug

Ascentage’s PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies

Fineline Cube Jan 8, 2026

Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera

Fineline Cube Jan 7, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) and Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced...

Company Drug

Sanofi’s Tzield Wins FDA Priority Review for Pediatric T1D Expansion

Fineline Cube Jan 7, 2026

Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has accepted for...

Company Drug

Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80%

Fineline Cube Jan 7, 2026

Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have lowered list prices for their...

Company Deals

Lilly Nears $1 Billion Deal for Ventyx’s IBD Pipeline

Fineline Cube Jan 7, 2026

Eli Lilly (NYSE: LLY) is in advanced talks to acquire Ventyx Biosciences for more than...

Company Deals

Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal

Fineline Cube Jan 7, 2026

Nimbus Therapeutics announced a multi‑year research collaboration and global exclusive licensing agreement with Eli Lilly...

Company Drug

Yifan Pharmaceutical’s F-652 Wins NMPA IND for GVHD Therapy

Fineline Cube Jan 6, 2026

Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that its Recombinant Human Interleukin‑22‑Fc Fusion Protein for...

Policy / Regulatory

NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs

Fineline Cube Jan 6, 2026

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released the...

Company Deals

Mabwell’s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson’s Trials

Fineline Cube Jan 6, 2026

Mabwell (688062.SH) announced that its incubated investment company, SynuSight Biotech, has signed a non‑exclusive clinical...

Company Deals

Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases

Fineline Cube Jan 6, 2026

Earendil Labs, the overseas subsidiary of Helixon, announced a strategic collaboration with Sanofi (NASDAQ: SNY)...

Company Drug

Ark Biopharma’s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years

Fineline Cube Jan 6, 2026

Shanghai Ark Biopharmaceutical Co., Ltd. announced that Azstarys (serdexmethylphenidate, dexmethylphenidate) has been approved by China’s...

Company Drug

Hengrui’s HRS9531 and AR‑PROTAC Win NMPA IND Approval for Clinical Trials

Fineline Cube Jan 6, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that four drug candidates—HRS9531 (GLP‑1R/GIPR...

Company Drug

Genhouse Bio’s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals

Fineline Cube Jan 6, 2026

Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China’s...

Company Deals

Touchstone Medical Partners with INSPUR to Advance Healthcare AI and Medical Robots

Fineline Cube Jan 6, 2026

Touchstone International Medical Science Co., Ltd. (SHA: 688013) announced a strategic partnership with INSPUR Co.,...

Company Deals Drug

Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets

Fineline Cube Jan 6, 2026

Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced exclusive commercial cooperation and cornerstone investment agreements with...

Company Drug

Humanwell Healthcare’s HW221043 Receives NMPA Approval for Advanced Solid Tumor Trials

Fineline Cube Jan 6, 2026

Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that its independently developed HW221043 tablets have...

Company Deals

Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform

Fineline Cube Jan 6, 2026

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement...

Company Drug

Frontier Biotech’s FB7013 Wins NMPA IND for MASP‑2 siRNA in IgA Nephropathy

Fineline Cube Jan 5, 2026

Frontier Biotechnologies Inc. (SHA: 688221) announced that it has submitted an Investigational New Drug (IND)...

Posts pagination

1 … 40 41 42 … 645

Recent updates

  • Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
  • Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
  • Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa
  • Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases
  • Alphamab Oncology’s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Company Drug

Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.